Synthetic Biologics, Inc.

4:45 PM - 5:00 PM (PDT), Tuesday, June 14, 2022
Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need. The Company recently consummated the acquisition of VCN Biosciences, S.L. (VCN), which is developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. In addition, the Company's lead candidates are.
Ticker:
SYN
Exchange:
NYSE: American
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
VCN-01/SYN-004/SYN-020
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3